On International Women’s Day, leaders across Canada will reaffirm their commitment to gender equality. Health equity is a fundamental pillar of that promise. Yet when it comes to early breast cancer detection, equality in this country still depends on a woman’s postal code.

Despite a publicly funded health-care system, Canada delivers a fragmented patchwork of breast screening programs, one that advances at different speeds and is shaped by inconsistent interpretations of evidence and uneven political will.

Dense Breasts Canada’s 2026 Provincial Breast Screening Performance Tracker evaluated every province and territory against seven evidence-aligned best practices for early detection. Not one jurisdiction meets all seven. Quebec meets only one.

Breast cancer remains the most commonly diagnosed cancer in Canadian women. Nearly 32,000 will be diagnosed this year. One in eight women will develop the disease in her lifetime. Seventeen percent of cases occur in women in their 40s. Cancers diagnosed at younger ages are more likely to be aggressive and diagnosed at later stages.

Yet organized screening beginning at age 40 remains inconsistent. Seven provinces and territories allow self-referral at age 40. Others require women to wait until 43, 45, or 50. Nowhere are 40-year-olds routinely invited into screening programs with the same systematic outreach that begins at 50.

Breast density adds another layer of inequity. About 43 percent of women have dense breast tissue, which both increases cancer risk and makes mammograms less sensitive. But density notification policies differ by province. Access to essential additional screening for women with dense breasts differs by province. Even the clarity of information women receive about breast density differs by province.

Access to screening after age 74 also varies. Breast cancer risk increases with age. In eight jurisdictions, women may continue screening through self-referral. In others, access depends on a requisition, despite healthy 75-year-old Canadian women living, on average, another 10 to 13 years.

Screening policy shapes stage at diagnosis. Stage at diagnosis shapes survival. Stage I breast cancer has a five-year survival rate above 99 per cent. Stage IV falls closer to 33 per cent. Later detection means more aggressive treatment, longer therapy, and far greater human and health care costs.

An evidence-aligned system would include organized invitations at 40, standardized density notification, publicly funded supplemental screening for women with dense breasts, continued access beyond 74 when appropriate, and integration of technologies that improve detection accuracy.

No province currently delivers all of these components.

Next month, in April, following significant reforms to governance and transparency, the Canadian Task Force on Preventive Health Care will relaunch under a renewed structure. Its suspension in March 2025 left the breast cancer screening guideline update unfinished. Completing that guideline using current and inclusive evidence must now be its first priority.

National guidelines matter. Provinces rely on them. Clinicians reference them. When national guidance lags behind science, fragmentation deepens, inequities widen, and women pay the price.

The renewed Task Force has both an opportunity and a responsibility: to deliver modern, evidence-aligned breast screening guidelines that reflect current science, address inequities, and restore public confidence.

In a country that promises universal health care, early cancer detection should not vary by geography.

On International Women’s Day, Canada will celebrate equality. Until a woman’s access to early detection no longer depends on her postal code, we are not there.

Jennie Dale, DBC